Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance
therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus
infections and advanced fibrosis or cirrhosis.